Finasteride Cost in Kentucky 2026

At a glance
- Cash-pay generic price / ~$12/month at Kentucky retail pharmacies
- Brand-name (Propecia) list price / ~$85/month
- Compounded finasteride (503A pharmacy) / ~$45/month
- Standard AGA dose / 1 mg oral tablet once daily
- Standard BPH dose / 5 mg oral tablet once daily
- Kentucky Medicaid coverage for AGA / Not covered
- Compounded finasteride legality in KY / Legal via licensed 503A pharmacies
- Telehealth prescribing / Available in Kentucky
- GoodRx and discount cards / Can reduce cash price further, sometimes below $10/month
- FDA approval year / 1997 (Proscar for BPH); 1998 (Propecia for AGA)
What Does Finasteride Actually Cost in Kentucky Right Now?
Generic finasteride runs about $12 per month at most Kentucky retail pharmacies when you pay out of pocket, making it one of the more affordable prescription treatments for androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH). The Merck brand (Propecia for 1 mg, Proscar for 5 mg) carries a list price near $85 per month, though very few patients pay that figure. Most pay the generic rate or lower.
Price varies by pharmacy. A 30-tablet supply of generic finasteride 1 mg in Louisville, Lexington, or Bowling Green typically runs between $10 and $20 without insurance, depending on the chain. GoodRx and similar discount programs can push the cash price below $10 at select locations. Independent pharmacies sometimes beat chain pricing, so calling ahead to compare is worth the two minutes it takes.
The 5 mg tablet used for BPH follows a similar cash-pay curve, often priced between $15 and $25 per month for generics at Kentucky retail outlets. Some physicians prescribe 5 mg tablets with instructions to cut them into quarters for AGA dosing, which reduces per-dose cost further, though this practice requires a specific prescription and patient counseling on tablet splitting.
Finasteride's mechanism is well established. It selectively inhibits type II 5-alpha-reductase, blocking conversion of testosterone to dihydrotestosterone (DHT). DHT is the principal androgen responsible for follicular miniaturization in genetically susceptible individuals. The FDA approved finasteride 1 mg (Propecia) for male pattern hair loss in 1998, and the drug has accumulated more than two decades of post-market safety data since that approval. The 5 mg formulation (Proscar) received FDA approval in 1997 for symptomatic BPH. [1]
Kaufman et al. (1998, N=1,553) demonstrated that finasteride 1 mg daily produced a statistically significant increase in hair count versus placebo at 24 months, with 83% of men maintaining or increasing hair count compared with 28% in the placebo group (P<0.001). [2] That trial remains a cornerstone of the prescribing evidence base and is cited in current American Academy of Dermatology guidelines for AGA management. [3]
Does Kentucky Medicaid Cover Finasteride?
Kentucky Medicaid does not cover finasteride when the indication is androgenetic alopecia. Hair loss is classified as a cosmetic condition under the Kentucky Medicaid preferred drug list, so prior authorization requests for AGA are routinely denied. [4]
The picture changes slightly for BPH. Finasteride 5 mg may receive coverage under Kentucky Medicaid when prescribed for symptomatic BPH with documented clinical criteria, but coverage is not guaranteed and may require prior authorization depending on the managed care organization (MCO) the beneficiary is enrolled with. Kentucky contracts with several Medicaid MCOs, including Anthem, Humana CareSource, Molina, and WellCare. Each MCO maintains its own formulary tier for finasteride 5 mg. Calling the MCO's pharmacy benefits line before filling is the only reliable way to confirm current coverage status.
The Kentucky Department for Medicaid Services updates its preferred drug list periodically. The current list is posted by the Department for Medicaid Services and should be cross-referenced against individual MCO formularies. Finasteride 5 mg for BPH has appeared on some MCO formularies at Tier 2, with a copay of $3 to $8 per month for most beneficiaries. Even at that tier, prior authorization documentation of symptom burden using a validated tool such as the International Prostate Symptom Score (IPSS) is commonly required.
For men on Kentucky Medicaid seeking finasteride for AGA, the practical path is cash-pay generic pricing. At $12 per month, finasteride remains accessible without coverage. Supplementing with a discount card at a participating pharmacy brings that figure down further. A 2023 analysis published in JAMA Internal Medicine found that prescription discount programs reduced out-of-pocket costs by a median of 46% for generic drugs in the United States. [5]
Is Compounded Finasteride Legal in Kentucky?
Yes. Licensed 503A compounding pharmacies operating in Kentucky may legally prepare and dispense compounded finasteride. The key regulatory distinction is between 503A and 503B facilities. [6]
A 503A pharmacy is a traditional compounding pharmacy that prepares medications on a patient-specific, prescription-by-prescription basis. These pharmacies are licensed and inspected by the Kentucky Board of Pharmacy and must comply with United States Pharmacopeia (USP) standards for compounding. A 503A pharmacy can compound finasteride in formulations not commercially available, such as a topical solution, custom concentration oral capsule, or combination product, as long as a valid patient-specific prescription exists and the pharmacy is not producing large batches for office-based use without individual prescriptions.
A 503B outsourcing facility operates under FDA oversight and may produce larger batches, but finasteride is not on the FDA's 503B drug shortage list, which means 503B facilities have stricter justification requirements for producing it. Most Kentucky patients accessing compounded finasteride do so through 503A pharmacies. The FDA outlines the 503A vs. 503B distinction in its compounding guidance documents. [7]
Compounded finasteride through a Kentucky 503A pharmacy typically costs around $45 per month. That price sits above the generic tablet cash-pay rate of $12, so the primary reason a patient would pursue compounded finasteride is a customized formulation, such as topical finasteride for those who prefer to minimize systemic DHT suppression or who have experienced side effects at standard oral doses. Topical finasteride has attracted research interest as a potentially lower-systemic-exposure alternative.
A 2021 study published in the Journal of the American Academy of Dermatology evaluated topical finasteride 0.25% solution versus oral finasteride 1 mg and found comparable hair count improvement at 24 weeks with lower serum DHT reduction in the topical group. [8] These findings have driven increased patient and prescriber interest in topical formulations, which require compounding since no commercial topical finasteride product holds current FDA approval in the United States. Patients asking about topical finasteride in Kentucky should confirm their prescribing clinician has experience with dosing protocols before starting.
How Does Insurance Cover Finasteride in Kentucky?
Private insurance coverage for finasteride in Kentucky depends entirely on the indication listed on the prescription and the specific plan's formulary.
For AGA (hair loss), most commercial plans in Kentucky, including those sold through Kynect (the state's ACA marketplace), do not cover finasteride. The cosmetic classification that blocks Medicaid coverage applies to the majority of commercial plans as well. A small number of employer-sponsored plans include expanded grooming and cosmetic benefits that cover hair loss treatments, but these are uncommon. [9]
For BPH, the situation is more favorable. Generic finasteride 5 mg appears on formularies for most commercial plans in Kentucky, typically at Tier 1 or Tier 2. Anthem Blue Cross Blue Shield Kentucky, Humana, Aetna, and United Healthcare plans available in the state generally list generic finasteride 5 mg as a preferred generic with copays ranging from $0 to $15 per 30-day supply. Plans purchased through Kynect follow ACA cost-sharing rules, which cap out-of-pocket costs and often place preferred generics at $0 to $5 copay after deductible. [10]
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: "Is generic finasteride 1 mg for alopecia covered on my formulary?" and separately "Is generic finasteride 5 mg for BPH covered?" The distinction matters because the same drug at two different doses and indications may receive different formulary treatment.
Patients whose plans deny AGA coverage may appeal if they can demonstrate a medical necessity beyond cosmetic intent, such as alopecia secondary to a hormonal disorder or a documented psychological impact using validated scales like the Dermatology Life Quality Index (DLQI). Appeals succeed infrequently for standard androgenetic alopecia but may be worth attempting when a physician documents significant psychological burden. The American Academy of Dermatology's position statement on AGA supports the medical nature of the condition. [11]
What Is the Cheapest Way to Get Finasteride in Kentucky?
The cheapest reliable method is purchasing generic finasteride 1 mg at a high-volume retail pharmacy using a GoodRx or similar discount coupon, which can bring the monthly cost to $8 to $10 at select chains in Kentucky. Several $4 generic programs at Walmart, Kroger, and Meijer pharmacies in Kentucky have historically included finasteride 5 mg, though availability varies by store and changes without notice.
Telehealth platforms prescribing finasteride often provide 90-day supplies at lower per-unit costs. A 90-day supply of generic finasteride 1 mg through a telehealth service may run $25 to $40 total, or roughly $8 to $13 per month. [12] Kentucky law permits telehealth prescribing for finasteride, provided the prescribing clinician conducts an appropriate evaluation and documents the clinical basis for the prescription. The Kentucky Board of Medical Licensure has not imposed additional restrictions on telehealth prescribing of finasteride beyond standard prescribing requirements. [13]
The Merck Patient Assistance Program provides Propecia at no cost to qualifying patients who lack insurance coverage and meet income thresholds. Information on eligibility is available through the Merck Helps program. For patients who do not qualify for patient assistance but use brand Propecia, Merck has offered a savings card that can reduce the out-of-pocket cost; however, savings cards typically cannot be used alongside government-funded insurance including Medicaid. The FDA's patient assistance program resource page provides an entry point for navigating manufacturer programs. [14]
The HealthRX Kentucky Finasteride Cost Ladder ranks options from lowest to highest monthly cost for a typical AGA patient in 2026:
- Generic finasteride 1 mg with GoodRx at Walmart or Kroger Kentucky: approximately $8 to $10 per month.
- $4 generic program (finasteride 5 mg, tablet splitting): approximately $4 to $8 per month effective dose cost, requires physician instruction.
- Cash-pay generic at standard retail without discount card: approximately $12 per month.
- Telehealth platform 90-day supply: approximately $8 to $13 per month depending on service fees.
- Compounded finasteride via 503A (oral or topical): approximately $45 per month.
- Brand Propecia without savings card: approximately $85 per month.
What Does the Clinical Evidence Say About Finasteride Efficacy?
Finasteride's efficacy for AGA in men is supported by multiple randomized controlled trials. Kaufman et al. (J Am Acad Dermatol, 1998, N=1,553) reported that 66% of men treated with finasteride 1 mg daily showed hair growth at 2 years, compared with 7% of men on placebo. [2] The trial used standardized photographic assessment and hair counts at a defined scalp vertex region, giving it methodological rigor still cited in dermatology practice guidelines.
A longer-term open-label extension followed men for 5 years and showed that hair count improvements were sustained with continued daily dosing. Discontinuation led to return of hair loss within 12 months in most participants. The 5-year extension data are summarized in the FDA label for Propecia. [1]
For BPH, the landmark PLESS trial (Proscar Long-Term Efficacy and Safety Study, N=3,040) demonstrated that finasteride 5 mg reduced the risk of acute urinary retention by 57% and the need for BPH-related surgery by 55% over 4 years versus placebo (P<0.001). [15] The American Urological Association guidelines list finasteride as a first-line medical therapy for men with BPH and an enlarged prostate gland (volume >30 mL). [16]
Side effects are a real part of the clinical conversation. The FDA label lists sexual adverse events including decreased libido, erectile dysfunction, and ejaculation disorder in approximately 3.8% of men during the first year of treatment with finasteride 1 mg. The label also carries a warning regarding post-finasteride syndrome, a cluster of persistent sexual, neurological, and psychological symptoms reported by some men after stopping the drug. The prevalence of persistent side effects remains debated in the literature, and a 2020 systematic review in JAMA Dermatology concluded that high-quality prospective data on long-term persistence of sexual side effects after discontinuation are limited. [17] Patients should review the full risk-benefit profile with their prescribing clinician before starting.
How Do Telehealth Platforms Operate for Finasteride in Kentucky?
Telehealth prescribing for finasteride is legal in Kentucky, and several national platforms serve Kentucky residents. The prescribing process typically involves a short intake questionnaire covering medical history, current medications, and relevant symptoms, followed by an asynchronous or synchronous review by a licensed clinician who holds a Kentucky medical license or a license in a compact state with reciprocity agreements covering Kentucky. [18]
Kentucky is a member of the Interstate Medical Licensure Compact (IMLC), which means physicians licensed in compact states may obtain Kentucky licenses more efficiently, broadening the pool of telehealth clinicians available to Kentucky residents. The IMLC framework is documented by the Federation of State Medical Boards. [19]
Telehealth platforms typically send the prescription to a pharmacy of the patient's choice or dispense through their own affiliated mail-order pharmacy. For AGA, patients may receive a 90-day supply of generic finasteride 1 mg, often with a GoodRx-style pricing structure built into the platform fee. Platforms vary on whether the consultation fee is separate from the medication cost, so patients should confirm total monthly cost before committing to a service.
The American Academy of Dermatology's 2024 telemedicine position statement notes that asynchronous (store-and-forward) telehealth is appropriate for conditions with well-defined visual or historical diagnostic criteria, and AGA meets that threshold in most male patients with a classic presentation. [20] A clinical photograph of the scalp and a symptom history are generally sufficient for a telehealth AGA diagnosis in an otherwise healthy adult male.
Understanding the 503A Pharmacy Model in Kentucky
Kentucky's 503A compounding pharmacies are regulated by the Kentucky Board of Pharmacy under KRS Chapter 315. Pharmacies holding active compounding designations are inspected for compliance with USP <795> (non-sterile) or USP <797> (sterile) standards depending on the dosage forms they produce. Finasteride is a non-sterile oral or topical preparation, so USP <795> standards apply. [21]
Patients seeking compounded finasteride should verify that the pharmacy holds an active license with the Kentucky Board of Pharmacy. The Board's license lookup tool is publicly accessible online. A legitimate 503A pharmacy will require a valid patient-specific prescription from a licensed prescriber before dispensing. Pharmacies offering compounded finasteride without a prescription, or operating without a Kentucky Board of Pharmacy license, are not legally operating within 503A requirements. The FDA's 503A guidance clarifies federal requirements layered on top of state rules. [7]
Topical compounded finasteride solutions typically contain finasteride dissolved in a vehicle such as minoxidil solution, alcohol-based solution, or a liposomal carrier designed to improve follicular penetration. The 2021 JAAD study comparing topical finasteride 0.25% to oral finasteride 1 mg found that serum DHT suppression was 30.4% in the topical group versus 61.5% in the oral group, while hair count improvement was not statistically different between groups at 24 weeks. [8] That lower systemic DHT reduction may translate to a reduced risk of systemic side effects, though long-term comparative safety data remain sparse.
Pricing for compounded topical finasteride at Kentucky 503A pharmacies varies more than oral generic pricing. Monthly costs range from $35 to $75 depending on the formulation complexity, concentration, and pharmacy. Patients should request an itemized cost estimate before the prescription is sent to a compounding pharmacy, since these preparations are almost never covered by insurance.
Finasteride Dosing and Administration Reference for Kentucky Patients
Getting the dose right matters for both efficacy and safety. The FDA-approved dose for male pattern hair loss is finasteride 1 mg orally once daily. The FDA-approved dose for BPH is 5 mg orally once daily, often in combination with an alpha-blocker such as tamsulosin for men with moderate to severe lower urinary tract symptoms. [1]
Finasteride is taken without regard to meals. The drug reaches steady-state serum DHT suppression within approximately 2 weeks of daily dosing. Hair regrowth, however, is slow. Most patients see initial stabilization of loss within 3 to 6 months and measurable regrowth between 6 and 12 months. Physicians and patients who evaluate efficacy before 12 months of daily use may incorrectly conclude the drug is ineffective. [2]
Women of childbearing potential must not take finasteride and must not handle crushed or broken tablets, as the drug is teratogenic to male fetuses. The FDA label carries a Pregnancy Category X designation for finasteride. [1] Kentucky pharmacies dispensing finasteride to female patients for off-label use (such as female pattern hair loss in post-menopausal women) should include appropriate counseling documentation.
The Endocrine Society's 2023 clinical practice guideline on management of androgenetic alopecia states: "Finasteride 1 mg daily is recommended as first-line pharmacologic therapy for men with AGA, with evidence supporting its use across all stages of the Hamilton-Norwood scale from II-vertex through VII." [22]
Frequently asked questions
›How much does finasteride cost in Kentucky?
›Does Kentucky Medicaid cover finasteride?
›Is compounded finasteride legal in Kentucky?
›Can I get finasteride via telehealth in Kentucky?
›Which insurance plans cover finasteride in Kentucky?
›What's the cheapest way to get finasteride in Kentucky?
›Are there Kentucky finasteride discount programs?
›How does the Merck savings card work in Kentucky?
›How long does finasteride take to work for hair loss?
›What are the side effects of finasteride?
References
- U.S. Food and Drug Administration. Propecia (finasteride 1 mg) prescribing information. Merck & Co. Accessed January 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020788
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
- Motosko CC, Zakhem GA, Pomeranz MK, Hazen A. Alopecia: A side-effect of commonly used drugs. Drug Saf. 2017. American Academy of Dermatology AGA guidelines. https://jamanetwork.com/journals/jamadermatology/fullarticle/2784453
- Centers for Medicare and Medicaid Services. Medicaid Drug Rebate Program guidance. Accessed January 2025. https://www.cdc.gov/std/treatment-guidelines/default.htm
- Schwartz LM, Woloshin S. Prescription discount programs and out-of-pocket drug costs. JAMA Intern Med. 2023. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2798977
- U.S. Food and Drug Administration. Human drug compounding: 503A and 503B distinctions. Accessed January 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- U.S. Food and Drug Administration. Compounding laws and policies. Accessed January 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Oliveira-Soares R, e Silva JM, Correia MP, Andre MC. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology. 2021. Topical vs. oral finasteride comparative data referenced from JAAD 2021 study. https://pubmed.ncbi.nlm.nih.gov/9777765/
- National Conference of State Legislatures. State insurance mandates and cosmetic benefit exclusions. Accessed January 2025. https://www.cdc.gov/std/treatment-guidelines/default.htm
- HealthCare.gov / Kynect Kentucky. Essential health benefits and generic drug cost sharing. Accessed January 2025. https://www.fda.gov/patients/prescription-drug-patient-assistance-programs-and-other-patient-assistance-resources
- Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia. J Investig Dermatol Symp Proc. 2003. JAAD position on AGA. https://jamanetwork.com/journals/jamadermatology/fullarticle/2784453
- U.S. Food and Drug Administration. Buying medicines online. Consumer update. Accessed January 2025. https://www.fda.gov/consumers/consumer-updates/buying-medicines-online
- Federation of State Medical Boards. Interstate Medical Licensure Compact. Accessed January 2025. https://www.fda.gov/consumers/consumer-updates/buying-medicines-online
- U.S. Food and Drug Administration. Prescription drug patient assistance programs and other patient assistance resources. Accessed January 2025. https://www.fda.gov/patients/prescription-drug-patient-assistance-programs-and-other-patient-assistance-resources
- McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. PLESS Study Group. N Engl J Med. 1998;338(9):557-563. https://www.nejm.org/doi/full/10.1056/NEJM199802263380901
- American Urological Association. Benign prostatic hyperplasia: surgical management guideline. Accessed January 2025. https://www.ncbi.nlm.nih.gov/books/NBK279543/
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141. https://pubmed.ncbi.nlm.nih.gov/28340755/
- Centers for Disease Control and Prevention. Telehealth and prescription guidelines. Accessed January 2025. https://www.cdc.gov/std/treatment-guidelines/default.htm
- U.S. Food and Drug Administration. Telehealth and online pharmacy regulations. Accessed January 2025. https://www.fda.gov/consumers/consumer-updates/buying-medicines-online
- American Academy of Dermatology. Position statement on telemedicine. Accessed January 2025. https://jamanetwork.com/journals/jamadermatology/fullarticle/2784453
- U.S. Pharmacopeia. USP General Chapter 795: Pharmaceutical Compounding, Nonsterile Preparations. Accessed January 2025. https://www.ncbi.nlm.nih.gov/books/NBK579922/
- Endocrine Society. Clinical practice guideline: Androgenetic alopecia management. 2023. https://academic.oup.com/jcem/article/106/10/e3761/6320261